In the first pharmacogenetic study in AD with the bigenic genotype APOE-TOMM40, carriers of the TOMM40 poly T-S/S genotype were good responders, similar to APOE-3/3 carriers, while patients harboring the L/L variant were the worst responders. This evidence concerns the gene APOE and Alzheimer disease.